Sunday, December 29, 2024
HomeTagsCerebral amyloid angiopathy

cerebral amyloid angiopathy

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim results from the ongoing single ascending dose part of the Phase 1 study of...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics